Table 3. Examples of Rhenium-188-Labeled Therapeutic Agents Under Development using the Alumina-Based Tungsten-188/Rhenium-188 Generator Available from the Nuclear Medicine Program, Oak Ridge National Laboratory (*ORNL*) (July 2000)

Application	Agent	Principal Investigators/Institution	Comment/Status
Peptides for Tumor Therapy	***Re-188-Peptides***	Diatide, Inc., Londonderry, New Hampshire York Medical, Inc., Ontario, Canada Resolution Pharmaceuticals, Ontario, Canada	Peptide for lung tumor therapy Peptides for lung tumor therapy
New rhenium-188 "Bifunctional" Radiolabeling Approaches	***Hynic Chelates***	J. Bartis, Ph.D., *et al.,* Dupont Pharm., Boston, MA S. Guhlke, Ph.D, *et al.*, Bonn, Germany	
	Re(V)-HEDP "Kits"	S. Guhlke, Ph.D, *et al.*, Bonn, Germany J. Smalljohan,Ph.D., *et al.*, Vienna, Austria	
Monoclonal Antibodies for Therapy	***Re-188-Antibodies***	H. Hansen, M.D., *et al.*, Garden State Cancer Center, NJ Ferro-Flores, Ph.D., *et al.*, Toluca, Mexico N. Izago-Escobar, Havana, Cuba	Therapeutic "Bispecific" Antibodies "Direct" labeling methods
Magnetic Targeted Carrier ("MTC")	***Activated Carbon Particles***	Ferx, Inc., Arvada, Colorado	Rhenium-188-labeled particles are intra arterially injected and localized in target tissue with focusing magnet. Particles are extravasated and permanently trapped in target tissue.

FFK: 7/18/00 - File:Re-188-Clinical-Trials